Abstract
Monoclonal antibodies (mAbs) are a class of biotherapeutic against a range of major diseases, making a current market of $ 125 billion by 2020. The industrial production system of choice is the submerged cultivation of animal cells in large scale bioreactor. The structural complexity of mAbs, low cell growth velocity, use of complex culture media, sensitivity to temperature variations and…